Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial

INTRODUCTION: CD4 T regulatory cells (Tregs) are crucial for the maintenance of self-tolerance and are deficient in many common autoimmune diseases such as type 1 diabetes (T1D). Interleukin 2 (IL-2) plays a major role in the activation and function of Tregs and treatment with ultra-low dose (ULD) I...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Waldron-Lynch, Frank, Kareclas, Paula, Irons, Kathryn, Walker, Neil M, Mander, Adrian, Wicker, Linda S, Todd, John A, Bond, Simon
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2014
Gaiak:
Diabetes and Endocrinology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4054640/
https://ncbi.nlm.nih.gov/pubmed/24898091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2014-005559
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak